Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Olmetyle AMH 20 Tablet is a triple-combination antihypertensive formulation consisting of Olmesartan Medoxomil (20 mg), Amlodipine (5 mg), and Hydrochlorothiazide (12.5 mg). Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a calcium channel blocker that relaxes vascular smooth muscles to enhance blood flow. Hydrochlorothiazide, a thiazide diuretic, reduces plasma volume by promoting excretion of sodium and water. This three-pronged approach results in potent and sustained control of high blood pressure, improving cardiovascular outcomes and reducing the risk of stroke, heart failure, and renal complications.
Olmeslide AH 20 Tablet is generally well tolerated. Some patients may experience dizziness, headache, swelling of ankles (due to Amlodipine), or increased urination (due to Hydrochlorothiazide). Electrolyte imbalance, muscle cramps, or fatigue may rarely occur. Serious adverse effects are uncommon but require immediate medical attention.
Indicated for the management of essential hypertension, especially in patients who require a combination of three antihypertensive agents for effective blood pressure control. It is often prescribed when monotherapy or dual therapy fails to achieve target blood pressure.
Use under medical supervision only. Not recommended during pregnancy, especially in the second and third trimesters, due to the risk of fetal toxicity. Caution should be exercised in patients with renal or hepatic impairment. Regular monitoring of blood pressure, renal function, and electrolyte levels is advised.
Store at a temperature below 30°C, away from moisture and direct sunlight. Keep out of reach of children.
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan Medoxomil 20 mg tablet
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg tablet
Composition : Olmesartan medoxomil 20 mg + chlorthalidone 12.5 mg tablet
Composition : Nitroglycerine 2.6 mg Tablet
Composition : Nitroglycerine 6.4 mg Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Olmesartan Medoxomil 20 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg Tablet is a triple-combination antihypertensive medication used for the management of moderate to severe hypertension (high blood pressure). It combines Olmesartan Medoxomil (ARB), Amlodipine (calcium channel blocker), and Hydrochlorothiazide (diuretic), offering a multi-mechanism approach to effectively control blood pressure. This makes it a highly advanced product in the cardiology and cardiovascular care segment, with strong demand in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from strong and consistent demand from cardiologists, physicians, and specialty clinics. Triple-drug antihypertensive therapy is widely prescribed in difficult-to-control hypertension cases, ensuring high prescription value, repeat demand, and long-term market stability, making it a premium addition to any cardiovascular portfolio.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and antihypertensive segment with monopoly rights, quality-assured manufacturing standards, attractive promotional support, and reliable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from high prescription strength, strong demand in resistant hypertension cases, long-term patient usage, and increasing reliance on combination therapies, making this product a high-value and profitable addition to their pharmaceutical business when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in advanced cardiovascular and antihypertensive formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiac segment.